Clinical Trial Details

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) for ER+/HER2- Early Breast Cancer

IRB Protocol Number
AFT-66 / CAMBRIA-2

Clinical Trial Categories

  • Breast Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility:  Pre-, peri-, and post-menopausal women, and men ages 18 or older, diagnosed with early-stage ER+ and HER2- invasive breast cancer with intermediate-high or high risk of recurrence, who have completed definitive locoregional therapy and have no evidence of disease.

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.